Failed Drugs, Second Chances

A clinical trial that fails for the average patient often succeeds for a subpopulation. The CureForge Drug Repurposing & Rescue Institute is the federation’s research engine for finding those subpopulations. Ten specialized AI systems collaborate across conditional-treatment-effect inference at population scale across failed clinical trials, automated re-analysis of historical Phase 2 and Phase 3 outcomes, subpopulation identification through responder-subgroup discovery, repurposingcandidate scoring across cross-disease repurposing potential, pregnancy pharmacokinetic adjustment coordinated with the federation’s maternal institute, raredisease repurposing coordinated with the rare-disease institute, personalized repurposing coordinated with the n-of-one institute, intellectual-property status analysis distinguishing composition-of-matter versus method-of-use claims, Bayesian adaptive trial re-design for rescue trials, and federation-wide repurposing distribution. Every failed drug is a potential second-chance asset.

Value proposition:

• Conditional treatment-effect inference at population scale
• Subpopulation responder discovery from failed clinical trials
• Coordinated rescue-trial design and intellectual-property analysis